First up this month: my annual roundup of open access news. At Absolutely Maybe – Open Access 2019: A Year of Momentum on the Subscription Off-Ramp. A year of deals, deals, break-ups, and more deals, that ended with a bombshell!

The MetaBLIND study emerged with a result no-one expected. Where does it leave us? My summary and thoughts in The Renewed Debate About Blinding in Clinical Trials.

And I was delighted to join the editorial board for the Drugs and Therapeutics Bulletin (DTB). It's not a research journal: it's an independent drug bulletin, communicating about evidence, predominantly to drug prescribers in the UK. The DTB is the brainchild of the marvellous Andrew Herxheimer (1925–2016). Andrew was a wonderful man, with a remarkable life and family. Here's a selfie I took with him in 2015, and here's a post I wrote about him and his father – What Lies Beneath a Scientist's Life: A Father and Son Story. It's an honor to contribute to the publication I still think of as "his".